The clinical results from the OxAMI-PiCSO study—published in EuroIntervention and presented at EuroPCR (22 May–25 May, Paris, France)—provide further evidence for the use of the PiCSO system (Miracor) during stenting procedures to improve microcirculatory flow and perfusion of the infarcted area, leading to a significantly smaller residual infarct size after an acute myocardial infarction.
Giovanni Luigi De Maria (the Heart Centre, Oxford University Hospitals, Oxford, UK) presented the data at EuroPCR. Additional results from the PiCSO in an ACS study were presented during the meeting by Mohaned Egred (Freeman Hospital, Newcastle upon Tyne, UK). These showed that PiCSO-treated patients have a statistically smaller infarct size compared to a group of propensity-score matched control patients.
Adrian Banning (Heart Centre, Oxford University Hospitals, Oxford, UK), chief investigator of the ongoing OxAMI-PiCSO study, says: “These positive results show promise that the PiCSO system can be used safely and effectively as an adjunctive therapy during primary PCI. Results demonstrating PiCSO’s ability to reduce myocardial injury for STEMI patients is noticed at 24-hours post-procedure with the IMR technique. This therapy has the potential to change my practice for STEMI patients.”
Olivier Delporte, CEO of Miracor Medical, notes: “The OxAMI-PiCSO study is the second study to show that PiCSO reduces the myocardial damage in STEMI patients and I am pleased that this growing body of data further confirms the potential of our system to become standard practice for the treatment of STEMI patients.”
PiCSO therapy is provided during the stenting procedure of patients enduring acute myocardial infarct and intermittently increases pressure in the coronary venous system, which leads to an improved microcirculatory flow and improved perfusion of the infarcted area resulting in smaller residual infarct size after acute myocardial infarction compared to non-PiCSO treated patients.